Program highlights for the fiscal year ended March 31, 2025, along with recent developments, include: Patient with advanced/metastatic end-stage pancreatic cancer who responded to MDNA11 treatment ...

FB102 is a proprietary anti-CD122 monoclonal antibody being developed for autoimmune and autoimmune-related conditions. In other recent news, ...

FB102 is a proprietary anti-CD122 monoclonal antibody being developed for autoimmune and autoimmune-related conditions. In other recent news, Forte Biosciences, Inc. announced the results of its ...

AnaptysBio will discuss updated Phase 2b trial data for rosnilimab in rheumatoid arthritis on June 3, 2025. Quiver AI Summary. AnaptysBio, Inc. announced they will host an investor call and live ...

The FB102-101 Phase 1b celiac disease study enrolled 32 subjects 3:1 randomized (24 on FB102 and 8 on placebo). Subjects received 4 doses of FB102 (10 mg/kg) and underwent a 16 day gluten challenge.